Melasma Management: How I Do It

Authors

  • Allison Sutton, MD, FRCPC

Abstract

Melasma is a common acquired disorder of hyperpigmentation which has a strong predilection for females and is more common in individuals with Fitzpatrick skin phototypes III-VI. It is most common on the face but can occur on the neck, upper chest, extensor forearms and upper back.

The pathogenesis of melasma is both multifactorial and incompletely understood. There is an increase in epidermal and dermal melanin without a similar increase in the number of melanocytes. Melanocytes are enlarged with elongated dendrites and increased numbers of melanosomes. An increase in mast cells, dermal blood vessels, abnormalities of the basement membrane and solar elastosis can also be seen. The number of blood vessels, vessel size and density are all increased in lesional melasma skin. Increasing evidence is emerging that points to melasma as a disorder of photoaging in genetically predisposed individuals.

Author Biography

Allison Sutton, MD, FRCPC

Dr. Allison Sutton is the owner and medical director of West Dermatology in Vancouver, B.C. Before moving back to Vancouver, she worked on Faculty as the Director of Aesthetic Dermatology for the University of Texas’ Health Sciences Centre in San Antonio. Dr. Sutton received her medical degree from the University of British Columbia, completed her residency in dermatology at the University of Toronto, and did a fellowship in aesthetic dermatology in San Antonio, Texas. She is both a Fellow of the Royal College of Physicians and Surgeons of Canada as well as a Fellow of the American Academy of Dermatology. She is a clinical instructor at the University of British Columbia.

References

Nomakhosi M, Heidi A. Natural options for management of melasma, a review. J Cos Las Therapy. 2018;20:470-81.

Huerth K, Hassan S, Callendar V. Therapeutic insights in melasma and hyperpigmentation management. J Drugs Dermatol. 2019;18(8):718-29.

Kwon SH, Hwang YJ, Lee SK, Park KC. Hetergeneous pathology of melasma and its clinical implications. Int J Mol Sci. 2016;17:824-34.

Passeron T, Picardo M. Melasma, a photoaging disorder. Pigment Cell Melanoma Res. 2018;31:461-5.

Miller Monthrope Y. An update on the management of facial hyperpigmentation: is there anything to use other than hydroquinone? Canadian Dermatology Today. 2020;1(4);6-11.

Draelos Z. Skin lightening preparations and the hydroquinone controversy. Dermatologic Therapy. 2007;20:308-11.

Boukari F, Jourdan E, Fontas E, Montaudie H et al. Prevention of melasma relapses with sunscreen combining protection against UV and short wavelengths of visible light: a prospective randomized comparative trial. J Am Acad Dermatol. 2015;72(1):189-90.

Rodrigues M and Pandya A. Melasma: clinical diagnosis and management options. Austalasian Journal of Dermatology. 2015;56:151-63.

Ibrahim Z, Gheida S, El Maghraby G and Farag Z. Evaluation of the efficacy and safety of combinations of hydroquinone, glycolic acid, and hyaluronic acid in the treatment of melasma. J Cosmetic Dermatology. 2015;14:113-23.

Kwon SH, Na JI, Choi JY, Park KC. Melasma: updates and perspectives. Experimental Dermatology. 2019;28:704-8.

Published

2021-02-01

How to Cite

1.
Sutton A. Melasma Management: How I Do It. Can Dermatol Today [Internet]. 2021 Feb. 1 [cited 2024 May 20];2(1):19–22. Available from: https://canadiandermatologytoday.com/article/view/2-1-sutton

Issue

Section

Articles